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FUS is sequestered in nuclear aggregates in ALS 
patient fibroblasts
Jacob C. Schwartza, Elaine R. Podella, Steve S. W. Hanb,c, James D. Berryb, Kevin C. Egganc, 
and Thomas R. Cecha
aHoward Hughes Medical Institute, Department of Chemistry and Biochemistry and BioFrontiers Institute, University 
of Colorado, Boulder, CO 80309; bDepartment of Neurology, Massachusetts General Hospital, Boston, MA 02114; 
cHoward Hughes Medical Institute, Harvard Stem Cell Institute and Department of Stem Cell and Regenerative 
Biology, Harvard University, Cambridge, MA 02138
ABSTRACT  Mutations in the RNA-binding protein FUS have been shown to cause the neuro-
degenerative disease amyotrophic lateral sclerosis (ALS). We investigate whether mutant 
FUS protein in ALS patient–derived fibroblasts affects normal FUS functions in the nucleus. 
We investigated fibroblasts from two ALS patients possessing different FUS mutations and a 
normal control. Fibroblasts from these patients have their nuclear FUS protein trapped in 
SDS-resistant aggregates. Genome-wide analysis reveals an inappropriate accumulation of 
Ser-2 phosphorylation on RNA polymerase II (RNA Pol II) near the transcription start sites of 
625 genes for ALS patient cells and after small interfering RNA (siRNA) knockdown of FUS in 
normal fibroblasts. Furthermore, both the presence of mutant FUS protein and siRNA knock-
down of wild-type FUS correlate with altered distribution of RNA Pol II within fibroblast nu-
clei. A loss of FUS function in orchestrating Ser-2 phosphorylation of the CTD of RNA Pol II is 
detectable in ALS patient–derived fibroblasts expressing mutant FUS protein, even when the 
FUS protein remains largely nuclear. A likely explanation for this loss of function is the aggre-
gation of FUS protein in nuclei. Thus our results suggest a specific mechanism by which 
mutant FUS can have biological consequences other than by the formation of cytoplasmic 
aggregates.
INTRODUCTION
Fused in Sarcoma (FUS) is an abundant nuclear RNA-binding protein 
and is also known as Translocated in Liposarcoma (TLS). The FUS 
protein contains an RNA recognition motif and a zinc finger, both of 
which are capable of binding RNA (Iko et al., 2004; Schwartz et al., 
2013). At its N-terminus, FUS has a domain of low amino acid se-
quence complexity that can assemble into higher-order structures 
(Kato et al., 2012; Kwon et al., 2013).
FUS affects multiple levels of RNA biogenesis. FUS binds and 
recruits RNA polymerase II (RNA Pol II) directly to DNA, as well as 
inhibiting or redirecting the activity of multiple transcriptional activa-
tors (Zinszner et al., 1994; Immanuel et al., 1995; Hallier et al., 1998; 
Powers et al., 1998; Yang et al., 2000; Das et al., 2007; Wang et al., 
2008; Tan and Manley, 2010; Tan et al., 2012; Kwon et al., 2013; 
Schwartz et al., 2012, 2013). FUS interacts with several heteroge-
neous nuclear ribonucleoproteins, as well as with the U1 small nu-
clear ribonucleoprotein complex, and is reported to affect mRNA 
splicing (Zinszner et al., 1994; Calvio et al., 1995; Hackl and Luhrmann, 
1996; Hallier et al., 1998; Lerga et al., 2001; Hoell et al., 2011; Ishigaki, 
Masuda, et al., 2012; Lagier-Tourenne, Polymenidou, Hutt, et al., 
2012). FUS is also reported to affect mRNA transport (Zinszner et al., 
1997; Fujii, Okabe, et al., 2005; Fujii and Takumi, 2005).
One nuclear function of FUS is to bind the C-terminal domain 
(CTD) of RNA Pol II (Schwartz et al., 2012, 2013; Kwon et al., 2013). 
The  CTD  is  important  for  transcription  because  its  sequential 
phosphorylation on Ser-5 and Ser-2 of the repeat CTD sequence 
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knockdown,  indicating  a  loss  of  function  (Kabashi  et  al.,  2011). 
Finally, overexpression models of FUS have produced mixed results, 
including cytoplasmic aggregates without toxicity or toxicity without 
aggregates (Halliday et al., 2012).
To provide more insight regarding this unresolved question, we 
investigated the physical state and function of FUS in normal and 
ALS patient fibroblasts. Patient-derived fibroblasts provide a power-
ful tool because they can be cultured and grown in the large quanti-
ties needed for molecular biology experiments, possess the native 
genetic background of the patient, and have not been genetically 
manipulated and therefore would not have genetic artifacts due to 
artificial levels of expression of the FUS protein. We studied fibro-
blasts from two ALS patients with FUS mutations, wild-type fibro-
blast controls, and wild-type controls after small interfering RNA 
(siRNA)–mediated knockdown of FUS protein levels. We measured 
relative FUS protein levels in the nucleus and cytoplasm, phospho-
rylation status of RNA Pol II near transcription start sites (TSS), and 
localization of active RNA Pol II. We found evidence that 1) FUS is 
sequestered in nuclear aggregates, 2) RNA Pol II is inappropriately 
phosphorylated at Ser2 for a subset of genes, and 3) RNA Pol II is 
mislocalized in the nucleus in these ALS patient fibroblasts.
RESULTS
FUS is present in nuclear aggregates in ALS patient–derived 
fibroblasts
We cultured human fibroblasts with three genetic backgrounds. The 
first fibroblast culture (mFUS; Figure 1A), derived from a patient with 
familial ALS, has a homozygous and recessive point mutation in the 
NLS of FUS, H517Q (Kwiatkowski et al., 2009). The second fibro-
blast culture (ΔNLS; Figure 1A), derived from a patient with sporadic 
ALS, possesses a heterozygous insertion and frameshift mutation 
resulting in the loss of the entire NLS, M511Nfs*6. The third (wild 
type; Figure 1A) was from a sex-matched, unrelated, neurologically 
normal control.
All experiments were performed on dividing cells that had not 
entered senescence. The cell culture protocol (see Materials and 
Methods) was important, because if the cells did not maintain con-
tact with other cells, they quickly entered senescence. Doubling 
times were measured to be between 5 and 7 d for both wild-type 
and  ALS  patient-derived  fibroblasts.  Cells  were  split  once  every 
1–1.5 wk and fed three times per week (see Materials and Methods). 
With careful passaging, cells could be grown for >30 passages.
YSPTSPS regulates initiation and elongation of the polymerase and 
the binding of factors involved in mRNA processing. FUS regulates 
the  phosphorylation  status  of  the  CTD  at  Ser-2  (Schwartz  et al., 
2012). Because phosphorylation of Ser2 serves coordinately to reg-
ulate RNA splicing, polyadenylation, and trafficking, FUS regulation 
of this RNA Pol II modification provides one simple model for the 
broad effects of the FUS protein on multiple levels of RNA biogen-
esis (Glover-Cutter, Kim, et al., 2008; Munoz et al., 2009; Schwartz 
et al., 2012; Gu et al., 2013).
Mutations in FUS have been shown to be a cause of the neuro-
degenerative disease amyotrophic lateral sclerosis (ALS). FUS muta-
tions account for 5% of familial and 1% of sporadic ALS disease; 
mutations in FUS therefore have a similar frequency to those in 
TDP-43 but are less prominent than mutations in C9ORF72 and 
SOD1 as known genetic causes of the disease (Kwiatkowski et al., 
2009; Vance, Rogelj, Hortobagyi, De Vos, et al., 2009). Known ALS-
causing FUS mutations are mostly limited to the nuclear localization 
signal (NLS; Lattante et al., 2013). Histological staining after autopsy 
reveals cytoplasmic aggregates staining positive for FUS in motor 
neurons of ALS patients and cortical neurons of a subset of fronto-
temporal dementia patients (Mackenzie et al., 2011; Lattante et al., 
2013). These observations led to a model in which disruption of cy-
toplasmic shuttling of this protein may play a role in disease pathol-
ogy. Both loss-of-function and toxic gain-of-function models have 
been proposed to explain FUS-dependent pathology. For example, 
loss of FUS from the nucleus could disrupt the normal nuclear func-
tions of the protein. Alternatively or in addition, the presence of FUS 
or its aggregates in the cytoplasm could result in a toxic gain of 
function. A gain of function in disease pathology does not preclude 
additional loss of function or its role in pathology.
Convincing counterarguments can be made for either a loss- or 
gain-of-function model of FUS pathology. One problem with a loss-
of-function  model  is  that  several  ALS-causing  mutations  do  not 
cause  a  dramatic  reduction  in  nuclear  FUS  (Bosco  et  al.,  2010; 
Kwiatkowski et al., 2009; Vance et al., 2013). In certain model organ-
isms, cytoplasmic mislocalization seems sufficient to produce toxic-
ity  without  reduction  of  endogenous  and  nuclear  FUS  (Halliday 
et al., 2012). On the other hand, molecular observations upon ex-
pression of mutant FUS protein, including the loss of nuclear Gemini 
of coiled bodies (Gems), are consistent with a loss of FUS function 
(Yamazaki et al., 2012; Tsuiji et al., 2013). A zebrafish model shows 
that FUS- possessing, ALS-causing mutations fail to rescue a FUS 
FIGURE 1:  ALS patient fibroblasts expressing mutant FUS show FUS predominantly in nuclei. (A) Three cell lines were 
tested. mFUS is homozygous for a point mutation, H517Q. ΔNLS is heterozygous for a frameshift mutation deleting the 
entire nuclear localization signal, M511Nfs. Wild type is a sex-matched normal control. (B) Immunofluorescence 
microscopy reveals that FUS is almost entirely nuclear, except for the ΔNLS cell line, which shows some cytoplasmic 
localization. Scale bar (lower left), 10 μm.
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near  the  TSS  and  increasing  toward 
the gene terminus (a “canonical” distribu-
tion;  Kim,  Erickson,  et  al.,  2010;  Mayer, 
Lidschreiber, Siebert, et al., 2010), the loss 
of FUS leads to high Ser2P levels near the 
TSS  for  thousands  of  genes.  This  change 
was accompanied by higher RNA Pol II lev-
els near the TSS, which could reflect delayed 
promoter clearance, more pausing, or pre-
mature termination (Schwartz et al., 2012). 
This observation is therefore taken to be a 
loss-of-function phenotype.
We hypothesized that the aggregation 
of FUS in the nuclei of the ALS fibroblasts 
would  reduce  the  levels  of  active  FUS, 
which would then perturb Ser-2 phospho-
rylation of the CTD in a manner similar to a 
FUS knockdown. To test this idea, we per-
formed  chromatin  immunoprecipitation 
followed  by  high-throughput  sequencing 
(ChIP-seq) of RNA Pol II using an antibody 
that selectively binds CTD possessing the 
Ser2P modification. For simplicity, we defined expressed genes as 
the 15,000 genes with the highest total Ser2P density along the 
gene. However, our initial experiments gave an unexpected re-
sult:  the  majority  of  genes  expressed  in  wild-type  fibroblasts 
showed a distribution of Ser2P signal that was higher near the TSS 
than near the gene terminus (Figure 3A, dashed lines). This led us 
to conclude that Ser2P regulation in fibroblast cells differs from its 
regulation in HEK293T/17 cells (Schwartz et al., 2012). Indeed, we 
analyzed several publicly available Ser2P ChIP-seq data sets and 
found that many cell lines from a variety of tissues also show non-
canonical Ser2P distributions for a majority of genes (unpublished 
data).
Nevertheless, for mFUS and ΔNLS fibroblasts a subset of genes 
did show a greater averaged Ser2P near the TSS compared with 
wild-type fibroblasts. We hypothesized that genes directly affected 
by FUS should also show increased Ser2P near their TSS after siRNA 
treatment (siFUS) in wild-type fibroblasts. Our siFUS treatment dra-
matically reduced FUS mRNA levels seen by real-time PCR (Figure 
3B, inset) and protein levels seen by immunofluorescence (see pre-
ceding section). A total of 625 genes showed significantly higher 
Ser2P near their TSS for siFUS, mFUS, and ΔNLS fibroblasts than 
with untreated wild-type fibroblasts (Figure 3B). A Student’s t test 
comparing the Ser2P signals near the TSS of each sample to wild-
type fibroblasts found highly significant differences for these genes 
(see p value in Figure 3A). Ontological analysis of these 625 genes 
revealed no significant enrichment for genes of particular cellular 
pathways or processes. In wild-type fibroblasts, these 625 genes 
predominantly displayed canonical Ser2P (Figure 3A, solid line). The 
median of total Ser2P levels near the TSS for the 625 intersecting 
genes in wild-type cells was lower than that for all genes because 
these genes mostly have canonically distributed Ser2P, and the lev-
els for the 625 genes were higher in siFUS, mFUS, and ΔNLS sam-
ples (Figure 3C).
FUS has a granular distribution and partially colocalizes 
with RNA Pol II
FUS forms higher-order assemblies that bind and recruit RNA Pol II to 
gene promoters through interactions with the CTD (Schwartz et al., 
2012, 2013; Kwon et al., 2013). We therefore hypothesized that FUS 
organization in the nucleus may contribute to RNA Pol II organization 
By immunofluorescence (IF; Figure 1B), FUS was nuclear in wild-
type fibroblasts and remained nuclear in the mFUS fibroblasts. Par-
tial mislocalization of FUS to the cytoplasm was apparent only in the 
ΔNLS patient, consistent with previous literature (Kwiatkowski et al., 
2009; Bosco et al., 2010). The specificity of the antibody used for IF 
is indicated by the absence of FUS staining after siRNA knockdown 
(see final section of Results).
When we lysed whole cells in 4% lithium dodecyl sulfate (LDS) 
loading buffer, the total cellular FUS protein levels were the same in 
the three genetic backgrounds (Figure 2A, left). (Even though the 
predicted molecular weight of FUS is 55 kDa, the band for FUS pro-
tein appeared slightly above the 62-kDa molecular weight marker, 
which is consistent with previous work; Crozat et al., 1993.) When we 
fractionated cells by hypotonic lysis and performed Western analy-
sis after SDS–PAGE, we noted that FUS protein levels were reduced 
in  the  nucleus  of  mFUS  and  almost  undetectable  in  ΔNLS  cells 
(Figure 2A, right). In our fractionated samples, no FUS was observed 
in the cytoplasmic fraction (Figure 2B). Therefore we reasoned that 
FUS could exist in SDS-resistant aggregates, which may not migrate 
into the SDS–PAGE gel. To test whether FUS was trapped in SDS-
resistant aggregates, we performed Western analysis on cytoplas-
mic and nuclear fractions from the wild-type and ΔNLS fibroblasts 
using a dot blot rather than electrophoresis and found at least 90% 
(wild  type)  or  70%  (ΔNLS)  of  FUS  protein  to  be  present  in  the 
nucleus,  consistent  with  our  immunofluorescence  observations 
(Figure 2C). The nuclear aggregates in ΔNLS and mFUS cells were 
much  more  insoluble  after  hypotonic  lysis  and  were  resistant  to 
1–2% SDS, 1% Triton X-100, RNase A, DNase I, and benzonase, as 
well as boiling in loading buffer containing 50 mM dithiothreitol 
(DTT) or 5 mM β-mercaptoethanol (unpublished data). However, 
treating nuclear lysates with formic acid followed by sonication in 
loading buffer did allow some FUS protein to resolve in the well dur-
ing SDS–PAGE, consistent with the hypothesis that the protein ex-
isted in a higher-order protein complex (Figure 2D).
ALS patient–derived fibroblasts have altered Ser-2 
phosphorylation of RNA Pol II
The knockdown of FUS protein leads to inappropriate Ser-2 phos-
phorylation (Ser2P) on the CTD of RNA Pol II in HEK293T/17 cells 
(Schwartz et al., 2012). That is, instead of Ser2P levels being low 
FIGURE 2:  Mutant FUS is trapped in aggregates within nuclei of ALS patient fibroblasts. 
(A) Western analysis of whole-cell FUS protein reveals that levels between the three cell lines are 
the same (WC, left). For ΔNLS samples, FUS protein from isolated nuclei after hypotonic lysis 
fails to resolve by SDS–PAGE (Nuclei, right). (B) Cytoplasmic FUS (Cyto., left) is also not 
detectable by SDS–PAGE. (C) Dot blot analysis of FUS protein isolated from cytoplasmic 
(C) or nuclear (N) fractions reveals that FUS is predominantly nuclear, in agreement with 
immunofluorescence data. (D) Treatment of nuclear protein with formic acid (Form., right) 
partially disrupts FUS aggregates, allowing protein to accumulate in the well during SDS–PAGE.
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Loss of FUS or expression of mutant FUS disrupts RNA Pol II 
localization
We analyzed FUS and RNA Pol II Ser5P immunofluorescence in wild-
type fibroblasts and ALS patient–derived fibroblasts. Owing to the 
complex granular staining of FUS and RNA Pol II in these fibroblasts, 
we were not able to determine with confidence whether any change 
in colocalization of FUS and RNA Pol II granules existed between 
wild-type and ALS patient–derived fibroblasts.
The most striking difference between these samples was in the 
distribution of active Ser5P RNA Pol II. In wild-type cells, Ser5P con-
centrated into several large granules clearly demarked by the re-
duced DAPI staining (Figure 5A). However, in mFUS and ΔNLS cells, 
these  granules  appeared  increasingly  fragmented,  smaller,  and 
more numerous (Figure 5, B–D). The number of Ser5P granules per 
cell was measured for two technical replicates (n > 30 cells per sam-
ple), revealing a significant difference between wild-type and ALS 
patient–derived cells (Figure 5E). In addition, the diameters of gran-
ules were measured (n > 200 granules per sample) to reveal that the 
distribution of granule diameters was substantially smaller for mFUS 
and ΔNLS samples (Figure 5F).
We hypothesized that if changes in RNA Pol II distributions were 
due to a loss of FUS function, siFUS-treated wild-type fibroblasts 
should also show a similar trend. Ser5P distributions showed smaller 
but still discernible differences between siFUS and wild-type fibro-
blasts (Figure 5D). These differences were also statistically signifi-
cant both in the number of granules per cell and their size (Figure 5, 
in the nucleus. We observed in FUS immunofluorescence an uneven 
staining level throughout the nucleus and no staining in the nucleo-
lus. This observation agrees with reports that FUS distribution is gran-
ular, with certain subnuclear regions possessing a higher local con-
centration of FUS signal (Alliegro and Alliegro, 1996; Kino et al., 
2010).
We  stained  wild-type  fibroblasts  with  4′,6-diamidino-2-phe-
nylindole (DAPI) to visualize chromatin, an RNA Pol II antibody 
specific for the phosphorylated Ser-5 (Ser5P) mark to detect tran-
scriptionally active RNA Pol II, and an antibody specific for FUS. 
We noted that RNA Pol II Ser5P staining also appeared granular, 
with  dense  immunofluorescence  staining  within  areas  stained 
weakly for DAPI (Figure 4, A and B). This is consistent with active 
transcription occurring in regions of loose chromatin compaction, 
hence weaker staining by DAPI (Mo and Dynan, 2002; Zhu et al., 
2004; Cisse et al., 2013). FUS staining also appeared granular, with 
dense FUS staining localized to regions of less densely compacted 
chromatin (Figure 4A). FUS granules somewhat colocalized with 
RNA Pol II granules (Figure 4, A and C), similar to published re-
ports that FUS and its Drosophila homologue Cabeza localize to 
actively transcribed regions of chromosomal DNA (Immanuel et al., 
1995; Kuroda et al., 2000). However, some RNA Pol II granules 
were largely devoid of FUS staining (Figure 4A). This is consistent 
with the observation that by ChIP-seq, approximately one-third of 
actively transcribed genes are not bound by or regulated by FUS 
protein (Schwartz et al., 2012).
FIGURE 3:  A subset of genes shows accumulation of Ser-2 phosphorylation (Ser2P) on RNA Pol II in ALS patient cells 
and after siRNA knockdown. (A) Average Ser2P signal for either all expressed genes (Total, dashed line) or the 
625 genes at the intersect of B (Intersect, solid line) for wild-type cells, siFUS, mFUS, or ΔNLS cells. The p value is 
measured between normalized sum of Ser2P near the TSS for the intersect of treated compared with wild type and 
using the two-tailed Student’s t test assuming unequal variances. (B) Using the threshold of twofold increase in Ser2P 
within 300 nucleotides of the transcription start site (TSS) with respect to wild-type cells, 625 genes show increased 
Ser2P in both ALS patient cells and after siRNA knockdown of FUS in wild-type cells (siFUS). See inset (right) for relative 
mRNA levels of FUS in siFUS-treated cells measured by real-time PCR. (C) Median Ser2P signal for either all expressed 
genes (Total) or the 625 genes at the intersect of B (Intersect). Error bars represent 25th and 75th percentiles. RPM, 
reads per million.
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argue for a loss of FUS function: inappropriate Ser2P near the TSS of 
some genes and a disruption in the distribution of active RNA Pol II 
in the nucleus. These observations, along with reported disruptions 
in Gem formation and splicing defects, support the argument for a 
loss of normal FUS function associated with mutations in the NLS 
(Kabashi et al., 2011; Lagier-Tourenne, Polymenidou, Hutt, et al., 
2012; Yamazaki et al., 2012; Tsuiji et al., 2013). We therefore present 
E and F). This again supports the hypothesis that the redistribution 
of RNA Pol II is due to a loss of FUS function.
DISCUSSION
We report here that FUS is sequestered in nuclear aggregates in fi-
broblasts derived from two ALS patients with FUS mutations We 
also make two new observations in the ALS patient fibroblasts that 
FIGURE 4:  FUS and RNA Pol II immunofluorescence reveal their substantial colocalization and concentration in areas 
stained weakly by DAPI. (A) Nuclei stained with DAPI (stains DNA) and immunofluorescence for Ser5P (active RNA Pol II) 
and FUS. Both FUS and RNA Pol II show granular staining patterns within the nucleus of wild-type fibroblast cells. Yellow 
lines indicate line profiles quantified in B and C. (B) Quantification of relative fluorescence units (RFU) for Ser5P (red) and 
DAPI (blue) along the line in A, lower left. (C) Quantification of RFU for Ser5P (red) and FUS (green) along the line in A, 
lower right.
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FUS aggregation remain untested. For example, phosphorylation of 
the  N-terminal  low-  complexity  (LC)  domain  of  the  FUS  protein 
modulates  the  ability  to  form  molecular  assemblies  (Kato  et  al., 
2012). Furthermore, methylation of arginines in the RGG motifs of 
FUS  is  modulated  by  nuclear–cytoplasmic  shuttling  of  the  FUS 
protein (Tradewell, Yu, et al., 2012; Yamaguchi and Kitajo, 2012; 
Scaramuzzino, Monaghan, et al., 2013). Whether arginine methyla-
tion affects aggregation itself is not known. Finally, the homologue 
of FUS, EWSR1, has been noted to be modified in its LC domain 
by  O-GlcNAc,  which  regulates  its  ability  to  affect  transcription 
(Bachmaier et al., 2009). If FUS is found to be O-GlcNAc modified 
like EWSR1, then modifications that have the potential to affect FUS 
assembly may not be limited to phosphorylation or methylation.
In summary, our observations strengthen the conclusion that FUS 
function is compromised by ALS disease–causing mutations. Fur-
thermore, we present a clear mechanism for this loss of function—
the entrapment of FUS protein in nuclear aggregates. Whether such 
nuclear aggregation also occurs in motor neurons is a key unan-
swered question. The mechanism by which FUS is entrapped in 
these nuclear aggregates also remains to be established. Neverthe-
less, even though the ΔNLS fibroblasts clearly show cytoplasmic 
FUS protein, our dot blot analysis suggests that the bulk of aggre-
gated FUS protein in these cells is, in fact, in the nucleus. The iden-
tification and characterization of this aggregation represents a sig-
nificant step forward in our understanding of normal FUS biology 
and the molecular consequences of ALS-causing FUS mutations.
MATERIALS AND METHODS
Cell culture
Fibroblast  cells  were  grown  in  DMEM  (Life  Technologies,  Grand 
Island,  NY)  supplemented  with  10%  fetal  bovine  serum  (FBS), 
Gluta-max (Life Technologies, Carlsbad, CA), and penicillin/ampicil-
lin antibiotics. Cells were fed with fresh media three times per week. 
Cells were maintained at a high confluency (no less than 70% conflu-
ency or 1.2 million cells/15-cm dish) and split 1:2 every 1–1.5 wk. At 
harvest, ∼2–2.5 million cells were recovered from each 15-cm dish. 
Cells were transfected with siRNA targeting FUS (Schwartz et al., 
2012) at a 25 nM final concentration using RNAiMAX (Life Technolo-
gies; 19.2 μl/15-cm dish) using the reverse-transfection protocol. 
RNAiMAX and siRNA were incubated for 20 min in Optimem (Life 
Technologies), and then 1.2 million cells were added and the vol-
ume brought up to 20 ml with normal growth medium.
Western analysis
Cells were grown to high confluency (2.4 million cells/dish) and har-
vested  with  0.25%  trypsin  (Life  Technologies).  Cell  pellets  were 
washed with phosphate-buffered saline (PBS) and cells counted to 
control  for  loading.  Total  cell  lysates  were  prepared  by  adding 
4× NuPage LDS sample buffer (Life Technologies) directly to cell 
pellets, boiling at 95ºC for 5 min, and loading equal cell numbers 
onto NuPage 4–12% Bis-Tris gels (Life Technologies). Nuclear and 
cytoplasmic fractions were separated by incubating cells with hypo-
tonic lysis buffer (10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 3 mM 
MgCl2, and 0.5% [vol/vol] NP-40) for 4 min on ice. Lysis was moni-
tored by microscopy to ensure that nuclei were intact. Nuclei were 
pelleted by centrifugation (500 × g for 4 min) and the supernatant 
saved as the cytoplasmic fraction. Nuclei were lysed in lysis buffer 
(50 mM Tris HCl, 120 mM NaCl, 1% SDS, 1 mM EDTA, 50 mM DTT, 
and protease inhibitor cocktail [Roche, Indianapolis, IN]), sonicated, 
and boiled at 95ºC for 5 min. Each was diluted into 1× NuPage LDS 
sample buffer, loaded onto a NuPage 4x12% Bis-Tris gel, and run in 
NuPage MES SDS running buffer (Life Technologies).
a model in which loss of FUS function observed here and in other 
published reports is due to FUS protein being trapped in nuclear 
aggregates. Of course, the existence of a loss of FUS function does 
not preclude an additional gain of function for the mutant protein.
The increase in Ser-2 phosphorylation for a subset of genes is 
consistent with a loss of FUS function. In our previous studies, we 
noted that the majority of genes in HEK293T/17 cells had much less 
Ser-2 phosphorylation near the TSS compared with the gene termi-
nus. Therefore genome-wide changes in Ser2P upon loss of FUS 
were large and affected thousands of genes. Ser2P distributions 
were  significantly  different  in  fibroblast  cells  compared  with 
HEK293T/17 cells, a result that we did not anticipate. Despite this 
difference,  a  subset  of  625  genes  was  identified  that  showed 
changes in Ser2P upon mutation or siRNA knockdown of FUS. The 
observation that Ser2P is regulated differently in these fibroblasts 
provides evidence of a deficit in a nonneuronal cell type and raises 
further questions about how this modification may be regulated in 
motor neurons, the cells whose dysfunction is central to ALS dis-
ease. Ser2P is noted to affect RNA splicing, and human and mouse 
neuronal splicing is reported to be more affected by FUS mutations 
than for other cell types (Lagier-Tourenne, Polymenidou, Hutt, et al., 
2012; Schwartz et al., 2012; Tsuiji et al., 2013).
FUS protein has a granular localization within the nucleus of fi-
broblast cells. The fact that these FUS granules overlap with sites 
enriched for active RNA Pol II is consistent with our previous finding 
in HEK293T/17 cells that FUS binds RNA Pol II near the TSS of many 
genes (Schwartz et al., 2012; Tan et al., 2012). That the colocaliza-
tion is imperfect agrees with the fact that a significant subset of ac-
tively  transcribed  genes  did  not  show  enrichment  for  FUS  in 
HEK293T/17 cells (Schwartz et al., 2012; Tan et al., 2012). The deter-
minants of this specificity remain unknown. Although RNA binding 
is important for FUS to bind the CTD, FUS binds RNA promiscuously 
in vitro. The in vivo observation that regions of active RNA Pol II are 
spatially segregated in the nucleus from regions enriched for FUS 
may suggest a role for nuclear structures and organization in deter-
mining whether a specific gene is regulated by FUS (Meissner et al., 
2003).
Finally, we report that the granular localization of active Ser5P 
RNA Pol II is altered in cells possessing FUS mutations. Granular 
staining of Ser5P RNA Pol II is more dramatic in fibroblasts than in 
HeLa or HEK293T/17 cells (unpublished data), which we hypothe-
size may be due to the slow cell cycle of fibroblasts compared with 
transformed cell lines. It is possible that these differences are even 
larger in nondividing neurons. However, it is not known to what ex-
tent disruptions in the granular localization of Ser5P leads to any 
further disruption in global transcription. We cannot exclude the 
possibility that these differences in Ser5P localization provide a clear 
marker of a loss in FUS function but have no further significance to 
normal cell biology.
Whereas nuclear aggregates can explain why FUS function is 
compromised, why NLS mutations cause nuclear aggregation of 
FUS is unclear. The simplest expectation for a loss of FUS function 
would be that NLS mutations would impede nuclear import and 
thereby lead to inappropriate cytoplasmic localization of FUS, which 
indeed is supported by some reports using overexpressed protein 
(Bosco et al., 2010; Kino et al., 2010; Vance et al., 2013). Alterna-
tively, the NLS may have some additional function within the nu-
cleus. Our in vitro studies with purified mutant FUS proteins revealed 
no changes in RNA binding, CTD binding, or formation of higher-
order protein assemblies that might shed light on the nuclear ag-
gregation (our unpublished data; Sun, Diaz, et al., 2011). A number 
of additional candidates for changes that might promote mutant Volume 25  September 1, 2014  FUS nuclear aggregates in ALS  |  2577 
Proteins were transferred to Amersham Hybond ECL membrane 
(GE  Healthcare,  Piscataway,  NJ)  by  electroblotting  using  0.5  A 
for 2 h. For dot blotting, lysates were added to 150 μl of transfer 
buffer and spotted onto the Hybond ECL membrane using a dot 
blot apparatus. Blots were probed with anti-FUS (4H11; sc-47711; 
Santa  Cruz  Biotechnology,  Dallas,  TX),  anti-H3  (ab1791;  Abcam, 
Cambridge, UK), or anti–glyceraldehyde-3-phosphate dehydroge-
nase (sc-137179; Santa Cruz Biotechnology).
ChIP-seq experiments
Twenty 15-cm dishes were transfected or seeded without transfec-
tion for each fibroblast cell culture. Cells were allowed to grow for 
5 d after transfection before harvesting. ChIP experiments were per-
formed essentially as described (Schwartz et al., 2012). Cells were 
cross-linked in 1% formaldehyde solution in PBS. Cross-linking was 
stopped by addition of 125 mM glycine dissolved in PBS. Cells were 
harvested by scraping and combined. Cells were lysed in lysis buffer 
(1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, 1× protease inhibi-
tors [Roche]) and sonicated for 15 min with a Bioruptor (Diagenode, 
Denville, NJ) per the manufacturer’s recommendations. Lysates were 
diluted 10-fold in IP buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM 
EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl, 1× protease inhibi-
tors [Roche]) and 10 μg of antibodies against Ser2P RNA Pol II as 
described (Schwartz et al., 2012).
Immunofluorescence
Forty thousand cells were transfected with siRNA or seeded without 
transfection onto poly-l-lysine–coated cover slips (Neuvitro, El Monte, 
CA) in 12-well dishes and grown for 5 d. Cells were cross-linked with 
4% formaldehyde (Sigma-Aldrich, St. Louis, MO) in PBS for 15 min at 
room temperature with shaking. Cells were washed three times with 
PBS and then incubated for 1 h at room temperature in permeabiliza-
tion/blocking buffer (0.5% Triton X-100, 3% bovine serum albumin in 
PBS). Antibodies were then added at 1:350 dilutions and incubated 
with shaking for 1–2 h at 30ºC. Slides were washed three times with 
PBS at room temperature. Slides were mounted with Vectashield 
(Vector Laboratories, Burlingame, CA) mounting medium with DAPI, 
sealed with nail polish, and allowed to dry overnight.
Antibodies used were anti-FUS (4H11; sc-47711; Santa Cruz Bio-
technology) or anti-Ser5P (ab5131; Abcam). Secondary antibodies 
used were Alexa Fluor 546 donkey anti-mouse or Alexa Fluor 633 
goat anti-rabbit (Life Technologies). Images were collected on a Del-
taVision Elite System (GE Healthcare) using a 60× objective. Images 
shown are a representative slice from a z-stack (3.5- to 7.5-μm stack, 
0.5-μm slices).
Image analysis
Images were analyzed using ImageJ software (National Institutes of 
Health, Bethesda, MD). Quantification began with randomization of 
images in order to blind the researcher performing the analysis. 
Each slice was inspected to ensure continuity of granules through 
the z-slices. Numbers of maxima were counted (n = 30–35 cells, two 
biological replicates), and the widest diameter among the slices was 
measured (n = 200–250 granules, two biological replicates).
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